diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular products, today announced that its Board of Directors has appointed Adeoye (Oye) Y. Olukotun, M.D., M.P.H., F.A.C.C., F.A.H.A. as an independent director. Dr. Olukotun brings 35 years of medical experience to diaDexus, having worked in management positions across large pharmaceutical, biotechnology and major medical device companies. He currently serves as vice chairman of CardioVax, LLC and is an active board member for Nordion Inc.
“As a board certified cardiologist and experienced biotechnology and pharmaceutical company leader, Dr. Olukotun brings a unique mix of clinical, regulatory and commercial expertise in the cardiology space to diaDexus,” said Brian Ward, Ph.D., diaDexus' president and chief executive officer. “His experience will be critical as we prepare to seek FDA clearance of our Activity test in the U.S. and begin developing a robust pipeline of cardiovascular diagnostic products.”
Dr. Olukotun is a board certified cardiologist who has been instrumental in the submission of many New Drug Applications, Premarket Authorization Applications and 510(k) Applications. Prior to CardioVax, a company that seeks to advance technologies in the treatment of cardiovascular disease caused by atherosclerosis, Dr. Olukotun was a co-founder and chief medical officer at VIA Pharmaceuticals, a biotechnology company focused on the treatment of cardiovascular and metabolic diseases. Prior to that, he was the chief medical officer and senior vice president of clinical and regulatory affairs at Esperion Therapeutics, a cardiovascular drug development company, until its acquisition by Pfizer. From 1996 to 2000, Dr. Olukotun was vice president of medical and regulatory affairs and chief medical officer of Mallinckrodt, Inc., a global pharmaceutical company. Dr. Olukotun holds a B.A. degree in chemistry from the University of North Carolina, a M.D. degree from Albert Einstein College of Medicine and a M.P.H. degree from Harvard University School of Public Health. He trained in cardiovascular diseases and did his fellowship at Mayo Clinic in Rochester, Minnesota.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts